PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1401820
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1401820
Antisense & RNAI Therapeutics Market size was valued at USD 3,800 Million in 2022, expanding at a CAGR of 19.1% from 2023 to 2030.
Antisense technology, acknowledged for gene expression manipulation, stands as a successful treatment avenue for numerous medical conditions. The use of Antisense and RNAi therapies for rare diseases has notably improved therapeutic outcomes. For example, Antisense Oligonucleotides (ASOs) have gained approval for treating rare neurological conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), signaling anticipated growth in the upcoming years. Additionally, augmented R&D funding and a robust product pipeline are expected to drive market expansion. For instance, in January 2023, Agilent invested USD 725 million in expanding manufacturing capabilities for nucleic acid-based therapeutics, including antisense therapies. The scarcity of global treatment options for rare diseases has spurred increased funding and research endeavors focused on developing novel treatments for these conditions.
Antisense & RNAI Therapeutics Market- Market Dynamics
Transformative impact of antisense and RNAi therapeutics in treating rare diseases to propel market demand
The primary factors driving the market are the transformative impact of antisense and RNAi therapeutics in treating rare diseases. By employing gene silencing, these therapies prevent the production of disease-related proteins, notably benefiting conditions like spinal muscular atrophy and heterozygous familial hypercholesterolemia. The precision and selectivity of RNAi treatments, which target disease-causing mRNA, position them as advanced and favored treatments for rare ailments. This surge in demand for RNAi therapeutics acts as a key driver, complemented by increased R&D investment and promising pipeline products, collectively propelling market expansion.
Antisense & RNAI Therapeutics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.1% over the forecast period (2023-2030)
Based on Technology segmentation, antisense RNA was predicted to show maximum market share in the year 2022
Based on Route of Administration segmentation, genetic disease was the leading type in 2022
On the basis of region, North America was the leading revenue generator in 2022
The Global Antisense & RNAI Therapeutics Market is segmented on the basis of Technology, Application, Route of Administration, and Region.
The market is divided into two categories based on Technology: RNA Interference and Antisense RNA. In 2022, the antisense RNA division represented the largest share of revenue. This segment has predominantly led in revenue generation and is actively undergoing trials for managing various conditions. Utilized for regulating both protein and gene expression, this technology exhibits broad applications across cardiovascular, respiratory, neurodegenerative, and genetic disorders, foreseeing significant segmental growth. For instance, a clinical trial at UMass Chan Medical School in December 2021 demonstrated the safe suppression of the mutant amyotrophic lateral sclerosis (ALS) gene using antisense oligonucleotides.
The market is divided into nine categories based on Route of Administration: Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardio Metabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders and Others. The genetic disorder sector commanded the highest revenue share in 2022. The growing necessity to manage diseases like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy is expected to drive the usage of oligonucleotide products. Research endeavors in the realm of oligonucleotide medications are rapidly expanding, evident from the increasing number of research studies. Companies are pursuing regulatory approvals for products designed to treat genetic diseases. For instance, in December 2019, golodirsen, an antisense oligonucleotide therapy for individuals afflicted with DMD, received approval from the Food and Drug Administration (FDA).
Antisense & RNAI Therapeutics Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
In the Antisense & RNAi Therapeutics Market, companies deploy various key strategies to bolster their position. They prioritize extensive research and development, investing in cutting-edge technologies to pinpoint precise gene targets and create effective therapeutic molecules. Diversifying pipelines remains a top priority, aiming to encompass a wide array of diseases and broaden market reach. Collaborative partnerships with research institutions and industry counterparts expedite progress and facilitate resource sharing. Concurrently, companies ensure rigorous compliance with regulatory standards, efficiently navigating approval processes. Post-approval, strategic commercialization plans, inclusive of targeted marketing and accessibility initiatives, are vital for successful adoption. Furthermore, continuous advancements in delivery systems are a pivotal focus to optimize therapeutic efficacy. These comprehensive strategies collectively drive the progression and acceptance of antisense and RNAi therapies within the healthcare landscape. Companies capitalize on antisense & RNAi technologies through dedicated advancements.
In April 2020, Alnylam Pharmaceuticals, Inc. partnered with Blackstone, with Blackstone investing USD 2 billion to accelerate RNAi therapeutics advancement.
The scope of this report covers the market by its major segments, which include as follows: